知柏地黄丸联合骨瓜提取物注射液治疗绝经后骨质疏松症 70 例疗效评价

目的探讨知柏地黄丸联合骨瓜提取物注射液治疗绝经后骨质疏松症（PMOP）的临床疗效。方法将140例患者分为治疗组和对照组各70例。两组均口服钙尔奇D片，对照组采用阿伦膦酸钠维生素D3片口服。治疗组采用骨瓜提取物注射液静脉滴注及知柏地黄丸口服。疗程均为6个月。观察两组患者治疗前后骨密度、血清钙和磷水平、疼痛评分变化。结果治疗组总有效率为92．9％（65／70），优于对照组的80．0％（56／70），差异有统计学意义（P〈0.05）；治疗组L1-4和全髋骨密度增加优于对照组，差异有统计学意义（P〈0.01）；治疗组血清钙水平低于对照组，差异有统计学意义（P〈0.05）；治疗组对疼痛的改善优于对照组，差异有统计学意义（P〈0．05）。结论知柏地黄丸联合骨瓜提取物注射液治疗PMOP（肝肾阴虚证）临床疗效肯定，安全性好，值得进一步推广。

Therapeutic evaluation of Zhibaidihuang pill combined with Gugua extractives injection in the treatment of 70 patients with postmenopausal osteoporosis

Objective To investigate the clinical efficacy of Zhibaidihuang pill combined with Gugua extractive injection in the treatment of postmenopausa] osteoporosis（PMOP）. Methods A total of 140 patients were randomly divided into treatment group and control group with 70 cases in each. Both groups were given Caltrate with vitamin D tablets orally,while the control group was with Allen risedronate sodium vitamin D3 tablets orally and the treatment group was treated with Zhibaidihuang pill o- rally combined with Gugua extractive injection. Course of treatment in both groups was 6 months. To observe the changes of bone mineral density ,the level of serum calcium and phosphorus ,pain scores of the patients in the two groups before and after treat- ment. Results The total effective rate of treatment group was 92.9% （65/70） ,which was superior to that of the control group （80.0%, 56/70）, and the difference between the two groups had statistical significance （P〈0.05）. Both the increase of L1_4 and the increase of total hip in the treatment group were higher than those in the control group with statistically significant difference （P〈0.01）. The serum calcium in the treatment group was lower than that in the control group with statistically significant difference （P〈0.05）. The pain improvement in the treatment group was better than that in the control group with statistically significant differecne （P〈0.05）. Conclusion Zhibaidihuang pill combined with Gugua extraetives injection has clinical effect in treating PMOP（syn- drome of yin deficiency of liver and kidney） with good safety, so it is worthy of further promotion.